SINGAPORE, 7 November 2023 – Duke-NUS Medical School (Duke-NUS) and IPGaia, Inc. (IPG) have signed an agreement to jointly advance drug discovery and development from academia to industry, to bring the benefits of translational research to patients. Through this partnership, Duke-NUS will propose drug targets to IPG, which will, in turn, identify and develop lead compounds with the goal of licensing clinic-ready candidates to pharmaceutical companies. The collaboration brings together IPG’s expertise in commercial research and development and its industry network with Duke-NUS’ strong capabilities in world-class discovery research in areas of global importance. Aligning with Singapore’s national focus to build a vibrant ecosystem for biomedical innovation, Duke-NUS’ five …
Thirty Companies have Accepted to Join IPG Membership
IPGaia, Inc., (“IPG”) operates IPG membership, which was established with the mission of providing pharmaceutical companies with more efficient access to clinical development drug candidates. We are happy to announce today that the number of member companies accepting IPG membership has exceeded thirty domestic and foreign pharmaceutical companies. Ten out of the thirty member companies are global pharmaceutical companies from abroad, and seven of the fifteen top pharmaceutical companies by revenue in the world (according to our research) have accepted to join the IPG membership. IPG is a platform provider for drug discovery and development in pre-clinical stage, and the company efficiently generates high-quality clinical development candidates from drug discovery …
Continue reading “Thirty Companies have Accepted to Join IPG Membership”
IP Gaia and PassPort Technologies Announce the Partnership Agreement
PassPort Technologies, Inc. (“PPTI”) and IP Gaia, Inc. (“IPG”) have entered into a business commissioning agreement (the “Agreement”) regarding business development activities aimed at partnerships with third parties for PPTI’s platform technology and development pipeline. Through this Agreement, PPTI will be able to leverage IPG’s network for business development activities. Mr. Tomoyuki Fujisawa, the President and CEO of PPTI, stated, “IPG’s extensive network with numerous global pharmaceutical companies is the ultimate business development capability, and it is like a dream function for venture companies like ours. Through the partnership with IPG, we are confident that we can timely deliver our innovative pharmaceuticals and new technologies to partner companies.” Yasunori Yamaguchi, …
Continue reading “IP Gaia and PassPort Technologies Announce the Partnership Agreement”